Castenmiller Suzanne M, Borst Anne L, Wardak Leyma, Molenaar Jan J, Papadopoulou Maria, de Krijger Ronald R, van der Steeg Alida Fw, van Noesel Max M, Vermijlen David, de Groot Rosa, Wienke Judith, Wolkers Monika C
Sanquin Blood Supply Foundation, Department of Research, T Cell Differentiation Lab, Amsterdam, The Netherlands.
Landsteiner Laboratory, Amsterdam Institute for Infection and Immunity, Cancer Center Amsterdam-Cancer Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Life Sci Alliance. 2025 Sep 2;8(11). doi: 10.26508/lsa.202503249. Print 2025 Nov.
High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New treatment options are thus required. Even though HLA expression in neuroblastoma is low and immune cell infiltrates are limited, the presence of tumor-infiltrating lymphocytes (TILs) is indicative of better patient survival. Here, we show that most tumor lesions contain viable immune cell infiltrates after induction chemotherapy, with high percentages of CD3 T cells. We therefore expanded the TILs and tested their antitumoral activity. With sufficient starting material, TIL expansion was as efficient as for adult solid tumors. However, whereas TIL products from adult tumors almost exclusively contained αβ T cells, in neuroblastoma-derived TIL products, γδ T cells expanded with similar efficacy as αβ T cells. Importantly, the antitumor responses in response to autologous tumor digest primarily originated from (Vδ1- and Vδ3-expressing) γδ T cells, and not from αβ T cells. In conclusion, this finding creates a window of opportunity for immunotherapy for neuroblastoma patients, with γδ T cells as potential prime responders.
尽管采用了强化治疗方案,高危儿科神经母细胞瘤患者的生存率仍很低。因此需要新的治疗选择。尽管神经母细胞瘤中的HLA表达较低且免疫细胞浸润有限,但肿瘤浸润淋巴细胞(TIL)的存在表明患者生存率较高。在此,我们表明大多数肿瘤病灶在诱导化疗后含有存活的免疫细胞浸润,其中CD3 T细胞百分比很高。因此,我们扩增了TIL并测试了它们的抗肿瘤活性。有足够的起始材料时,TIL扩增与成人实体瘤一样有效。然而,成人肿瘤来源的TIL产物几乎只含有αβ T细胞,而神经母细胞瘤来源的TIL产物中,γδ T细胞的扩增效率与αβ T细胞相似。重要的是,对自体肿瘤消化物的抗肿瘤反应主要源自(表达Vδ1和Vδ3的)γδ T细胞,而非αβ T细胞。总之,这一发现为神经母细胞瘤患者的免疫治疗创造了机会窗口,γδ T细胞可能是主要的反应细胞。